BRPI1011453A2 - formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina - Google Patents
formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapinaInfo
- Publication number
- BRPI1011453A2 BRPI1011453A2 BRPI1011453A BRPI1011453A BRPI1011453A2 BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2 BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- drug
- dosage form
- asenapine hemipamoate
- hemipamoate salt
- Prior art date
Links
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 title 1
- 229960005245 asenapine Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22002709P | 2009-06-24 | 2009-06-24 | |
| PCT/EP2010/058960 WO2010149727A2 (en) | 2009-06-24 | 2010-06-24 | Injectable formulations containing asenapine and method of treatment using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011453A2 true BRPI1011453A2 (pt) | 2016-03-15 |
Family
ID=43386952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011453A BRPI1011453A2 (pt) | 2009-06-24 | 2010-06-24 | formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8658687B2 (pt) |
| EP (1) | EP2453870A2 (pt) |
| JP (1) | JP5801295B2 (pt) |
| KR (1) | KR101435296B1 (pt) |
| CN (1) | CN102596172A (pt) |
| AR (1) | AR077225A1 (pt) |
| AU (1) | AU2010264670A1 (pt) |
| BR (1) | BRPI1011453A2 (pt) |
| CA (1) | CA2766291C (pt) |
| MX (1) | MX2012000061A (pt) |
| RU (1) | RU2012102247A (pt) |
| TW (1) | TW201113018A (pt) |
| WO (1) | WO2010149727A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524920A1 (en) * | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Asenapine Hydrochloride Salt Forms |
| EP2524921A1 (en) * | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Salts of Asenapine |
| TWI552751B (zh) * | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法 |
| US10022445B2 (en) * | 2012-07-26 | 2018-07-17 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
| CA2890270A1 (en) * | 2012-11-01 | 2014-05-08 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition of tapentadol for parenteral administration |
| FR3020810B1 (fr) * | 2014-05-06 | 2016-05-06 | Servier Lab | Nouveau sel de l'ivabradine et son procede de preparation. |
| US11154510B2 (en) | 2015-06-11 | 2021-10-26 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
| RU2762896C2 (ru) | 2016-12-20 | 2021-12-23 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин |
| RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
| RS67063B1 (sr) * | 2017-01-09 | 2025-08-29 | Relmada Therapeutics Inc | Injektabilne suspenzije |
| BR112019027037B1 (pt) | 2017-06-26 | 2022-04-05 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema |
| PH12020550555B1 (en) * | 2017-11-07 | 2024-03-06 | Intervet Int Bv | Injectable isoxazoline pharmaceutical compositions and uses thereof |
| UA127892C2 (uk) * | 2017-11-07 | 2024-02-07 | Інтервет Інтернешнл Б.В. | Спосіб одержання частинок ізоксазоліну великого розміру |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US11648213B2 (en) | 2018-06-20 | 2023-05-16 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| JP7537811B2 (ja) * | 2020-08-26 | 2024-08-21 | 上海雲晟研新生物科技有限公司 | カリプラジン医薬組成物、製造方法及び応用 |
| JP2025508811A (ja) * | 2022-02-22 | 2025-04-10 | 上海雲晟研新生物科技有限公司 | カリプラジン薬用塩及びその結晶形、医薬組成物、製造方法並びに使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| ZA933134B (en) * | 1992-05-08 | 1993-11-30 | Akzo Nv | Depot preparation |
| EP0569096A1 (en) * | 1992-05-08 | 1993-11-10 | Akzo Nobel N.V. | Depot preparation |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| AU7767598A (en) * | 1997-05-26 | 1998-12-30 | Akzo Nobel N.V. | Salts of aromatic sulphonic acids |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| TR200000812T2 (tr) | 1997-09-30 | 2001-07-23 | Eli Lilly And Company | 2-metil-tieno- benzodiazepin formülasyonu. |
| BRPI0516000A (pt) * | 2004-10-15 | 2008-05-06 | Pfizer | uso de um composto ou de um sal, solvato, hidrato ou isÈmero óptico farmaceuticamente aceitável do mesmo, método para tratar distúrbio bipolar em um mamìfero em necessidade do mesmo, e, kit para uso no tratamento de distúrbios bipolares |
| DK1710241T3 (da) * | 2005-04-07 | 2010-03-01 | Organon Nv | Intermediatforbindelser til fremstilling af trans-5-chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol |
| GT200600135A (es) * | 2005-04-07 | 2006-11-07 | Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales | |
| TW200817414A (en) | 2006-07-05 | 2008-04-16 | Organon Nv | Process for the preparation of asenapine and intermediate products used in said process |
| MX2010007404A (es) | 2008-01-04 | 2010-10-05 | Organon Nv | Procedimiento para la preparacion de asenapina y productos intermediarios utilizados en dicho procedimiento. |
-
2010
- 2010-06-24 AU AU2010264670A patent/AU2010264670A1/en not_active Abandoned
- 2010-06-24 BR BRPI1011453A patent/BRPI1011453A2/pt not_active Application Discontinuation
- 2010-06-24 KR KR1020127001815A patent/KR101435296B1/ko active Active
- 2010-06-24 RU RU2012102247/15A patent/RU2012102247A/ru unknown
- 2010-06-24 WO PCT/EP2010/058960 patent/WO2010149727A2/en not_active Ceased
- 2010-06-24 TW TW099120654A patent/TW201113018A/zh unknown
- 2010-06-24 JP JP2012516732A patent/JP5801295B2/ja active Active
- 2010-06-24 EP EP10725792A patent/EP2453870A2/en not_active Withdrawn
- 2010-06-24 CN CN2010800378161A patent/CN102596172A/zh active Pending
- 2010-06-24 CA CA2766291A patent/CA2766291C/en not_active Expired - Fee Related
- 2010-06-24 MX MX2012000061A patent/MX2012000061A/es not_active Application Discontinuation
- 2010-06-24 AR ARP100102242A patent/AR077225A1/es not_active Application Discontinuation
- 2010-06-24 US US13/378,118 patent/US8658687B2/en active Active
-
2013
- 2013-12-17 US US14/109,633 patent/US20140154322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR077225A1 (es) | 2011-08-10 |
| CA2766291A1 (en) | 2010-12-29 |
| KR20120030561A (ko) | 2012-03-28 |
| US20140154322A1 (en) | 2014-06-05 |
| AU2010264670A1 (en) | 2012-01-19 |
| KR101435296B1 (ko) | 2014-08-27 |
| EP2453870A2 (en) | 2012-05-23 |
| MX2012000061A (es) | 2012-06-01 |
| CA2766291C (en) | 2016-06-21 |
| TW201113018A (en) | 2011-04-16 |
| WO2010149727A3 (en) | 2011-04-21 |
| JP2012530759A (ja) | 2012-12-06 |
| US8658687B2 (en) | 2014-02-25 |
| RU2012102247A (ru) | 2013-07-27 |
| JP5801295B2 (ja) | 2015-10-28 |
| US20120237561A1 (en) | 2012-09-20 |
| CN102596172A (zh) | 2012-07-18 |
| WO2010149727A2 (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011453A2 (pt) | formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina | |
| NL301291I2 (nl) | sparsentan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301248I2 (nl) | atogepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301157I2 (nl) | odevixibat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301187I2 (nl) | Rimegepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301035I2 (nl) | upadacitinib of een farmaceutisch aanvaardbaar zout daarvan | |
| BRPI0906467A2 (pt) | forma de dose farmacêutica | |
| NL300901I2 (nl) | pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan | |
| SMT201500209B (it) | Forme di dosaggio farmaceutiche a rilascio controllato | |
| IL229409B (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| IL245328A0 (en) | Pharmaceutical composition | |
| ZA201304709B (en) | A pharmaceutical dosage form | |
| BR112015003376A8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| BR112012011902A2 (pt) | cápsula farmacêutica | |
| IL219276A0 (en) | Gastroretentive dosage forms of poorly soluble drugs | |
| BRPI1012246A2 (pt) | composição farmacêutica contendo um fármaco e sirna | |
| DK2652652T3 (da) | Medikmentadministration | |
| EP2568979A4 (en) | RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION | |
| SI2582366T1 (sl) | Farmacevtska kombinacija za zdravljenje bolečine | |
| IL231622B (en) | Pharmaceutical composition for treatment of cachexia | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer | |
| PT2665471T (pt) | Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg | |
| BR112012031102A2 (pt) | forma de dosagem oral sólida | |
| BR112014015885A8 (pt) | preparação farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |